| Gina Teresa Cardona, CNM | |
|
10101 Se Main St Ste 3001, Portland, OR 97216-2458 | |
| (503) 261-4423 | |
| (503) 261-4424 |
| Full Name | Gina Teresa Cardona |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 10101 Se Main St Ste 3001, Portland, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316178197 | NPI | - | NPPES |
| 022959 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 201402768NP-PP (Oregon) | Primary |
| Entity Name | Multnomah County |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609914787 PECOS PAC ID: 6608771787 Enrollment ID: O20031203000025 |
News Archive
Much as predators attack their prey in the animal world, there are bacteria that consume and kill other bacteria. Scientists are reporting new progress in putting the predator microbes to work - to attack dangerous bacteria that cause eye infections that lead to blindness and have grown resistant to antibiotics.
A clinical trial has begun which will use stem cell transplants to grow a new immune system for people with untreatable Crohn's disease - a painful and chronic intestinal disease which affects at least 115,000 people in the UK.
Caris Life Sciences announced today data from two studies presented at the 2013 European Cancer Congress, which demonstrate the potential of evidence-guided molecular profiling to immediately improve the treatment of patients with hard-to-treat cancers, including cancers of unknown primary (CUP) origins as well as rare tumors and cancers that have been refractory to treatment.
Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd RDEA594, 600 mg qd RDEA594 or matching placebo.
Essential Learning, the leading provider of e-learning solutions to the behavioral health and human service industries, is pleased to announce a new partnership with Hazelden, a nonprofit organization for addiction treatment and publisher of treatment, behavioral health and youth violence educational resources.
› Verified 7 days ago
| Entity Name | Womens Healthcare Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346296142 PECOS PAC ID: 8527054014 Enrollment ID: O20040421000823 |
News Archive
Much as predators attack their prey in the animal world, there are bacteria that consume and kill other bacteria. Scientists are reporting new progress in putting the predator microbes to work - to attack dangerous bacteria that cause eye infections that lead to blindness and have grown resistant to antibiotics.
A clinical trial has begun which will use stem cell transplants to grow a new immune system for people with untreatable Crohn's disease - a painful and chronic intestinal disease which affects at least 115,000 people in the UK.
Caris Life Sciences announced today data from two studies presented at the 2013 European Cancer Congress, which demonstrate the potential of evidence-guided molecular profiling to immediately improve the treatment of patients with hard-to-treat cancers, including cancers of unknown primary (CUP) origins as well as rare tumors and cancers that have been refractory to treatment.
Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd RDEA594, 600 mg qd RDEA594 or matching placebo.
Essential Learning, the leading provider of e-learning solutions to the behavioral health and human service industries, is pleased to announce a new partnership with Hazelden, a nonprofit organization for addiction treatment and publisher of treatment, behavioral health and youth violence educational resources.
› Verified 7 days ago
| Entity Name | Portland Adventist Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750091021 PECOS PAC ID: 3274908819 Enrollment ID: O20230412001327 |
News Archive
Much as predators attack their prey in the animal world, there are bacteria that consume and kill other bacteria. Scientists are reporting new progress in putting the predator microbes to work - to attack dangerous bacteria that cause eye infections that lead to blindness and have grown resistant to antibiotics.
A clinical trial has begun which will use stem cell transplants to grow a new immune system for people with untreatable Crohn's disease - a painful and chronic intestinal disease which affects at least 115,000 people in the UK.
Caris Life Sciences announced today data from two studies presented at the 2013 European Cancer Congress, which demonstrate the potential of evidence-guided molecular profiling to immediately improve the treatment of patients with hard-to-treat cancers, including cancers of unknown primary (CUP) origins as well as rare tumors and cancers that have been refractory to treatment.
Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd RDEA594, 600 mg qd RDEA594 or matching placebo.
Essential Learning, the leading provider of e-learning solutions to the behavioral health and human service industries, is pleased to announce a new partnership with Hazelden, a nonprofit organization for addiction treatment and publisher of treatment, behavioral health and youth violence educational resources.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gina Teresa Cardona, CNM 1400 Sw 5th Ave Ste 500, Portland, OR 97201-5537 Ph: () - | Gina Teresa Cardona, CNM 10101 Se Main St Ste 3001, Portland, OR 97216-2458 Ph: (503) 261-4423 |
News Archive
Much as predators attack their prey in the animal world, there are bacteria that consume and kill other bacteria. Scientists are reporting new progress in putting the predator microbes to work - to attack dangerous bacteria that cause eye infections that lead to blindness and have grown resistant to antibiotics.
A clinical trial has begun which will use stem cell transplants to grow a new immune system for people with untreatable Crohn's disease - a painful and chronic intestinal disease which affects at least 115,000 people in the UK.
Caris Life Sciences announced today data from two studies presented at the 2013 European Cancer Congress, which demonstrate the potential of evidence-guided molecular profiling to immediately improve the treatment of patients with hard-to-treat cancers, including cancers of unknown primary (CUP) origins as well as rare tumors and cancers that have been refractory to treatment.
Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd RDEA594, 600 mg qd RDEA594 or matching placebo.
Essential Learning, the leading provider of e-learning solutions to the behavioral health and human service industries, is pleased to announce a new partnership with Hazelden, a nonprofit organization for addiction treatment and publisher of treatment, behavioral health and youth violence educational resources.
› Verified 7 days ago
Margaret R. Zak, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 9340 Sw Barnes Road, The Prenatal Clinic, Suite 102, Portland, OR 97225 Phone: 503-216-2859 | |
Margaret Elizabeth Shaw, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 3181 Sw Sam Jackson Park Rd, Portland, OR 97239 Phone: 503-494-4500 | |
Elise N Erickson, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 9427 Sw Barnes Rd, Suite 395, Portland, OR 97225 Phone: 503-216-2602 | |
Olivia Kroening-roche, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 3181 Sw Sam Jackson Park Rd, Portland, OR 97239 Phone: 503-494-7591 Fax: 503-494-7591 | |
Polly C Molden, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 3181 Sw Sam Jackson Park Rd, Portland, OR 97239 Phone: 503-418-4500 Fax: 503-494-1678 | |
Kelsey Tassinari Poppe, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 3455 Sw Us Veterans Hospital Rd, Portland, OR 97239 Phone: 503-494-7725 | |
Ms. Barbara O'malley Floyd, CNM, NMNP Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 3231 Se 50th Ave, Portland, OR 97206 Phone: 503-775-4931 Fax: 503-788-7285 |